Opthea

Opthea Limited is an Australian biotechnology company focused on developing innovative biologic therapies for eye diseases. Its lead compound, OPT-302, targets vascular endothelial growth factors, specifically VEGF-C and VEGF-D, which contribute to abnormal blood vessel growth and leakage, key factors in conditions such as wet age-related macular degeneration (wet AMD). The company’s research is underpinned by a strong intellectual property portfolio that includes key targets related to vascular and lymphatic vessel growth, as well as vascular leakage. Through its commitment to advancing treatments in this area, Opthea aims to address significant unmet medical needs in ocular health.